← Back to Screener
Ovid Therapeutics Inc. Common Stock (OVID)
Price$2.56
Value ScoreC
Growth ScoreB
Momentum ScoreA
Favorite Metrics
Price vs S&P 500 (26W)107.84%
Price vs S&P 500 (4W)-7.12%
VGM Score69.75
Market Capitalization$509.53M
All Metrics
Book Value / Share (Quarterly)$1.19
P/TBV (Annual)0.89x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)69.09%
Cash Flow / Share (Quarterly)$-0.25
Price vs S&P 500 (YTD)56.55%
Net Profit Margin (TTM)-240.13%
EPS (TTM)$-0.24
10-Day Avg Trading Volume1.27M
EPS Excl Extra (TTM)$-0.24
Revenue Growth (5Y)-10.46%
EPS (Annual)$-0.24
ROI (Annual)-13.33%
Net Profit Margin (5Y Avg)-4365.33%
Cash / Share (Quarterly)$0.93
Revenue Growth QoQ (YoY)844.74%
ROA (Last FY)-11.54%
Revenue Growth TTM (YoY)1199.64%
EBITD / Share (TTM)$-0.53
ROE (5Y Avg)-16.86%
Operating Margin (TTM)-585.20%
Cash Flow / Share (Annual)$-0.29
P/B Ratio2.57x
P/B Ratio (Quarterly)1.69x
Net Income / Employee (Annual)$-757,100
EV / Revenue (TTM)57.29x
ROA (TTM)-18.67%
EV / EBITDA (TTM)3.34x
EPS Incl Extra (Annual)$-0.24
Current Ratio (Annual)8.97x
Quick Ratio (Quarterly)9.88x
3-Month Avg Trading Volume2.66M
52-Week Price Return807.28%
Revenue / Employee (TTM)$309,700
Tangible BV / Share (Quarterly)$1.19
P/S Ratio (Annual)70.26x
Asset Turnover (Annual)0.05x
52-Week High$3.10
Operating Margin (5Y Avg)-6058.75%
EPS Excl Extra (Annual)$-0.24
CapEx CAGR (5Y)-4.25%
Tangible BV CAGR (5Y)24.72%
26-Week Price Return123.77%
Quick Ratio (Annual)8.40x
13-Week Price Return65.45%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)10.17x
Enterprise Value$415.46M
Revenue / Share Growth (5Y)-14.50%
Asset Turnover (TTM)0.08x
Book Value / Share Growth (5Y)8.63%
Revenue / Employee (Annual)$315,300
Pretax Margin (Annual)-240.13%
Cash / Share (Annual)$0.53
3-Month Return Std Dev77.51%
Net Income / Employee (TTM)$-1,050,700
ROE (Last FY)-13.33%
EPS Basic Excl Extra (Annual)$-0.24
Receivables Turnover (TTM)4168.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.24
ROI (TTM)-22.51%
P/S Ratio (TTM)70.26x
Pretax Margin (5Y Avg)-4365.20%
Revenue / Share (Annual)$0.10
Tangible BV / Share (Annual)$1.00
Price vs S&P 500 (52W)779.07%
Year-to-Date Return67.48%
5-Day Price Return10.53%
EPS Normalized (Annual)$-0.24
ROA (5Y Avg)-9.66%
Net Profit Margin (Annual)-240.13%
Month-to-Date Return-1.44%
Cash Flow / Share (TTM)$-0.68
EBITD / Share (Annual)$-0.57
Operating Margin (Annual)-585.20%
ROI (5Y Avg)-16.86%
EPS Basic Excl Extra (TTM)$-0.24
P/TBV (Quarterly)1.69x
P/B Ratio (Annual)0.89x
Pretax Margin (TTM)-240.13%
Book Value / Share (Annual)$1.00
Price vs S&P 500 (13W)55.71%
Beta0.22x
P/FCF (Annual)4.30x
Revenue / Share (TTM)$0.05
ROE (TTM)-22.51%
52-Week Low$0.27
vGradeC
gGradeB
mGradeA
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.12est. -0.12
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.38
4.38
4.35
4.35
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
OVIDOvid Therapeutics Inc. Common Stock | C | B | A | $2.56 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Ovid Therapeutics is a biopharmaceutical company developing novel treatments for rare epilepsies and seizure-related neurological disorders. The company's pipeline features multiple programs with potential first-in-class and best-in-class mechanisms of action, targeting patient populations with limited treatment options.